Translational Research Develops Intranasal Formulation of Granisetron, Antiemetic Agent.Tokyo, Japan, May 26, 2006 - (JCN) - Translational Research, a subsidiary of Shin Nippon Biomedical Laboratories, has developed an intranasal in·tra·na·sal (  n tr -n formulation of granisetron granisetron /gran·is·e·tron/ (gra-nis´e-tron) an antiemetic used in conjunction with cancer chemotherapy or radiotherapy, administered as the hydrochloride salt., an agent with antiemetic antiemetic /an·ti·emet·ic/ (-e-met´ik) preventing or alleviating nausea and vomiting; also, an agent that so acts.an·ti·e·met·ic (  n efficacy. Granisetron is commonly used in reducing side effects Side effects Effects of a proposed project on other parts of the firm. of antitumor therapy. In experiments on monkeys, the company confirmed that the new formulation has an immediate action equivalent to injections as well as excels in absorbability through nasal mucosa. The company expects that the new formulation may help improving the quality of life of cancer patients suffering from side effects. Going forward, the company plans to begin phase I clinical trials with a view to commercializing it around 2010. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion